REDMOND, Wash., April 22, 2024 /PRNewswire/ --SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Jie D'Elia, Ph.D., MBA, as its new Chief Executive Officer.

华盛顿州雷德蒙德，2024年4月22日/PRNewswire/--SystImmune，Inc.，一家开创性的临床阶段生物制药公司，专注于开发用于治疗癌症的新型治疗性双特异性，多特异性抗体和抗体-药物偶联物（ADC），今天宣布任命Jie D'Elia博士，MBA为其新任首席执行官。

With a diverse background spanning over two decades in the biopharmaceutical industry, Dr. D'Elia most recently served as Senior Vice President for business development in oncology, hematology, and cell therapy at Bristol Myers Squibb ('BMS'). Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation..

D'Elia博士在生物制药行业拥有20多年的丰富背景，最近担任百时美施贵宝（“BMS”）肿瘤学，血液学和细胞治疗业务发展高级副总裁。D'Elia博士在药物开发，战略规划和业务开发方面的丰富经验有望推动SystImmune进入下一个增长和创新阶段。。

Dr. Yi Zhu, Chairman of SystImmune, welcomed Dr. D'Elia to the SystImmune team, stating, 'Jie is an accomplished leader with a proven track record of developing business strategy, forging strategic collaborations, and cultivating high-performing teams. I look forward to working with her as we steer SystImmune towards new horizons of development and success.'.

SystImmune董事长朱毅博士欢迎D'Elia博士加入SystImmune团队，他说：“Jie是一位有成就的领导者，在制定业务战略、建立战略合作和培养高绩效团队方面有着良好的记录。我期待着与她合作，引领Systimune走向发展和成功的新视野。”。

Dr. D'Elia shared her enthusiasm for the new role, saying, 'SystImmune has carved a niche in the biopharmaceutical landscape with its success in developing first-in-class and best-in-class therapeutics. Its highly differentiated platforms discovering bi-specific and multi-specific antibodies and ADCs stand out as a testament to its innovative capabilities.

D'Elia博士分享了她对这一新角色的热情，她说：“SystImmune在生物制药领域已经占据了一席之地，它成功地开发了一流和一流的治疗方法。其高度分化的平台发现了双特异性和多特异性抗体以及ADC，这证明了其创新能力。

I am honored to join this accomplished team and am committed to advancing our pipeline of therapeutics to bring new treatment paradigms for patients in need.'.

我很荣幸加入这个有成就的团队，并致力于推进我们的治疗渠道，为有需要的患者带来新的治疗模式。”。

Before joining SystImmune, Dr. D'Elia spent over a decade at BMS where she made significant contributions to BMS's pipeline evolution through multiple strategic partnerships and acquisitions in therapeutic areas ranging from oncology, cardiovascular, virology, fibrosis, and cell therapy. Prior to BMS, Dr. D'Elia served as the Vice President and Global Head of Business Development at Simcere Pharmaceutical.

在加入SystImmune之前，D'Elia博士在BMS工作了十多年，通过在肿瘤学、心血管、病毒学、纤维化和细胞治疗等治疗领域的多项战略合作和收购，为BMS的管道发展做出了重大贡献。在加入BMS之前，D'Elia博士曾担任Simcere Pharmaceutical的副总裁兼全球业务发展负责人。

She previously worked at AstraZeneca, Boston Consulting Group and Baxter Healthcare. Throughout her career in the biopharmaceutical industry, Dr. D'Elia has orchestrated over $40 billion in strategic partnerships and mergers and acquisitions, leveraging her strong business expertise and deep industry knowledge.

她之前曾在阿斯利康（AstraZeneca）、波士顿咨询集团（Boston Consulting Group）和巴克斯特医疗（Baxter Healthcare）工作。在生物制药行业的整个职业生涯中，D'Elia博士利用其强大的商业专业知识和深厚的行业知识，在战略合作伙伴关系和并购方面协调了400多亿美元。

Dr. D'Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School..

D'Elia博士拥有德克萨斯大学奥斯汀分校药学院的博士学位和哥伦比亚商学院的MBA学位。。

About SystImmune

关于SystImmune

SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has multiple assets in various stages of clinical trials for solid tumor and hematologic indications.

SystImmune是一家临床阶段的生物制药公司，位于华盛顿州雷德蒙。它专门利用其已建立的药物开发平台开发创新的癌症治疗方法，重点关注双特异性，多特异性抗体和抗体-药物偶联物（ADC）。SystImmune在实体瘤和血液学适应症的不同临床试验阶段拥有多种资产。

Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development. .

除了正在进行的临床试验外，SystImmune在发现或IND启用阶段拥有强大的潜在癌症治疗药物临床前管道，代表了前沿生物制剂的发展。。

View original content to download multimedia:https://www.prnewswire.com/news-releases/systimmune-inc-appoints-dr-jie-delia-as-chief-executive-officer-302122763.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/systimmune-inc-appoints-dr-jie-delia-as-chief-executive-officer-302122763.html

SOURCE SystImmune, Inc.

SOURCE SystemImmune公司。